Cancer Research Technology
Log in Register
Menu

Anti-cROS [4-6G]

Invented by Dr Al Charest at Tufts University

Info

Catalogue Number 151666
Applications FACS IF IP Fn WB
Antigen/Gene or Protein Targets cROS
Reactivity Human
Relevance Monoclonal antibody directed against cROS, a proto-oncogene with therapeutic target potential.

Background and Research Application
c-ROS is a proto-oncogene tyrosine kinase, that is highly-expressed in a variety of tumour cell lines and belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. It is a type I integral membrane protein and may function as a growth or differentiation factor receptor. The c-ROS gene promoter region has been identified and characterized and it has been shown that the ectopic expression of c-ROS in tumours is tied to hypomethylation of a CpG island in the c-ROS promoter. Tumours with ROS1 mutations are typically responsive to small molecule tyrosine kinase inhibitors.
Host Mouse
Immunogen Extracellular portion of ROS amino acid 1-285 fused to Fc, transiently expressed in 293 cells and purified using PtnA column chromatography.
Immunogen UniProt ID P08922
Positive Control Cells transiently expressing human cROS, mouse cells expressing human cROS
Subclass IgG1
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions DMEM + 20% FCS low IgG
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
An intra-chromosomal deletion del(6)(q21q21) is responsible for the formation of GOPC-ROS1 chimeric protein which has a constitutive receptor tyrosine kinase activity.

Concentration
1mg/ml as standard
Research Area Cancer, Cell Signaling & Signal Transduction, Epigenetics & Nuclear Signalling

References

There are 6 reference entries for this reagent.

View All References

References: 6 entries

Fei et al. 2019. Biosci Rep. 39(6):. PMID: 31138757.

Zhang et al. 2019. Int J Biol Sci. 15(7):1460-1471. PMID: 31337976.

Shih et al. 2017. Oncogene. 36(47):6542-6554. PMID: 28759046.

Deng et al. 2014. Int J Mol Med. 34(3):661-8. PMID: 24968753.

Charest et al. 2003. Proc Natl Acad Sci U S A. 100(3):916-21. PMID: 12538861.

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Europe PMC ID: 12538861


Add a reference

References: 6 entries

Fei et al. 2019. Biosci Rep. 39(6):. PMID: 31138757.

Zhang et al. 2019. Int J Biol Sci. 15(7):1460-1471. PMID: 31337976.

Shih et al. 2017. Oncogene. 36(47):6542-6554. PMID: 28759046.

Deng et al. 2014. Int J Mol Med. 34(3):661-8. PMID: 24968753.

Charest et al. 2003. Proc Natl Acad Sci U S A. 100(3):916-21. PMID: 12538861.

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.


Add a reference